Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of KL003 Cell Injection for transfusion-dependent beta-thalassemia
CTR20240672Phase 2Active
- Sponsor
- Kanglin Biotechnology
- Start
- Apr 2024
- Modality
- Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of KL003 in beta thalassemia, sponsored by Kanglin Biotechnology. Started Apr 2024; status: active.
02
Drugs
KL003
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on CTR20240672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240672.